Roche, Al­ny­lam’s zilebe­sir­an suc­ceeds in an­oth­er PhII hy­per­ten­sion test

Al­ny­lam Phar­ma­ceu­ti­cals’ RNAi ther­a­py re­duced blood pres­sure in a Phase II hy­per­ten­sion test, mark­ing its sec­ond clin­i­cal suc­cess since Roche se­cured a deal for the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER